Technical Analysis for WVE - WAVE Life Sciences Ltd.

WAVE Life Sciences Pte. Ltd., a preclinical biopharmaceutical company, designs, develops, and commercializes nucleic acid therapeutic candidates. The company is developing nucleic acid therapeutics that target genetic defects to either reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins. Its advanced therapeutic programs are in Huntington's disease, Duchenne muscular dystrophy (DMD), and inflammatory bowel disease (IBD). In Huntington's disease, it has programs targeting HTT SNP-1 and HTT SNP-2; in DMD, targeting Exon 51; and in IBD, targeting SMAD7. The company also has product candidates in its programs targeting HTT SNP-1 and Exon 51. In addition, it has late-stage discovery programs in epidermolysis bullosa simplex, targeting KRT14 SNP-1 and KRT14 SNP-2, as well as in DMD, focuses on an additional DMD target, AcRIIb. The company was founded in 2012 and is based in Singapore.
Rare Diseases Medical Genetics Inflammatory Bowel Disease Muscular Dystrophy Huntington's Disease Duchenne Muscular Dystrophy Genetic Genealogy Genodermatoses Cytoskeleton Dystrophin Ibd SNP